Scholars@Duke
Susan Faye Dent

Susan Faye Dent

Adjunct Professor in the Department of Medicine
Medicine, Medical Oncology
susan.dent@duke.edu
DUMC 3446, Durham, NC 27710
DUMC 3446, Durham, NC 27710

Selected Publications

Breast cancer and cardiovascular health.

Journal Article Eur Heart J · November 7, 2024 Modern cancer therapies greatly improve clinical outcomes for both early and advanced breast cancer patients. However, these advances have raised concerns about potential short- and long-term toxicities, including cardiovascular toxicities. Therefore, unde ... Full text Link to item Cite

Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth.

Journal Article Sci Adv · September 27, 2024 Estrogens regulate eosinophilia in asthma and other inflammatory diseases. Further, peripheral eosinophilia and tumor-associated tissue eosinophilia (TATE) predicts a better response to immune checkpoint blockade (ICB) in breast cancer. However, how and if ... Full text Link to item Cite

Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES-Continuous Study.

Journal Article J Am Heart Assoc · August 6, 2024 BACKGROUND: Both cancer and cardiovascular disease (CVD) are the leading causes of death worldwide. Although our previous study detected a relationship between CVD and cancer incidence, limited evidence is available regarding the relationship between CVD, ... Full text Link to item Cite

Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer.

Conference Breast Cancer Res Treat · August 2024 PURPOSE: This study aimed to assess safety and efficacy of a modified KEYNOTE 522 protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose-dense (14 day) doxorubicin and cyclophosphamide (ddAC). By optimizing this dosing, the ... Full text Link to item Cite

Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer.

Journal Article J Am Heart Assoc · July 16, 2024 BACKGROUND: Cardiovascular disease and cancer share a common risk factor: chronic stress/allostatic load (AL). A 1-point increase in AL is linked to up to a 30% higher risk of major cardiac events (MACE) in patients with prostate cancer. However, AL's role ... Full text Link to item Cite

Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study.

Journal Article Am Heart J · January 2024 Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women with h ... Full text Link to item Cite

Moving Beyond Cardiotoxicity Detection to Prevention: A Pharmacologic Review

Journal Article Current Treatment Options in Cardiovascular Medicine · January 1, 2024 Purpose of review: Cardio-oncology is a subspecialty of medicine focused on minimizing the risk of cardiovascular (CV) toxicity in patients receiving potentially cardiotoxic cancer therapy. While the literature has previously focused on detection of CV tox ... Full text Cite

Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions.

Journal Article J Am Heart Assoc · November 7, 2023 Cardiotoxicity is a growing concern in the oncology population. Transthoracic echocardiography and multigated acquisition scans have been used for surveillance but are relatively insensitive and resource intensive. Innovative imaging techniques are constra ... Full text Link to item Cite

ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.

Journal Article Molecular oncology · October 2023 Taselisib is a potent β-sparing phosphatidylinositol 3-kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated (PIK3CAmut) advanced breast cancer. To ... Full text Cite

The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22.

Journal Article Eur J Prev Cardiol · September 20, 2023 AIMS: This study aimed to characterize the influence of a cancer diagnosis on the use of preventive cardiovascular measures in patients with and without cardiovascular disease (CVD). METHODS AND RESULTS: Data from the Behavioural Risk Factor Surveillance S ... Full text Link to item Cite

Social Determinants of Health and Racial Disparities in Cardiac Events in Breast Cancer.

Journal Article J Natl Compr Canc Netw · July 2023 BACKGROUND: Racial disparities have been reported for breast cancer and cardiovascular disease (CVD) outcomes. The determinants of racial disparities in CVD outcomes are not yet fully understood. We aimed to examine the impact of individual and neighborhoo ... Full text Link to item Cite

Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.

Journal Article J Am Heart Assoc · June 20, 2023 Background Cyclin-dependent kinase (CDK) 4 and 6 inhibitors have significantly improved survival in patients with hormone receptor-positive metastatic breast cancer. There are few data regarding the epidemiology of cardiovascular adverse events (CVAEs) wit ... Full text Link to item Cite

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.

Journal Article Genome Med · April 26, 2023 BACKGROUND: Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35-40% of patients with HR+/HER2- breast cancer. Preclinically, cancer cells harboring doub ... Full text Link to item Cite

Cardiometabolic Consequences of Targeted Anticancer Therapies.

Journal Article J Cardiovasc Pharmacol · October 1, 2022 Cardiometabolic disease (CMD) is the most common preventable cause of death in the world. A number of components are included in the spectrum of CMD, such as metabolic syndrome/obesity, hyperglycemia/diabetes, dyslipidemia, and hypertension, which are inde ... Full text Link to item Cite

Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology.

Journal Article JACC CardioOncol · September 2022 The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to grow as patients with cancer live longer as a result of lifesaving targ ... Full text Link to item Cite

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.

Journal Article JACC CardioOncol · June 2022 There are nearly 17 million cancer survivors in the United States, including those who are currently receiving cancer therapy with curative intent and expected to be long-term survivors, as well as those with chronic cancers such as metastatic disease or c ... Full text Open Access Link to item Cite

Using the Appropriate Formula for QT Measurement Can Save Lives.

Journal Article Hematology/oncology and stem cell therapy · March 2022 CDK 4/6 inhibitors, in combination with endocrine therapy, are the standard of care for patients with endocrinesensitive advanced breast cancer. This class of drug, however, is associated with QT prolongation, which serves as a surrogate marker for Torsade ... Full text Cite

Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis.

Journal Article Eur Heart J · January 31, 2022 AIMS: The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown. METHODS AND RESULTS: Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified femal ... Full text Link to item Cite

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

Journal Article European heart journal · January 2022 The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which ... Full text Cite

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.

Journal Article BMJ · December 8, 2021 OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate cons ... Full text Link to item Cite

Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer

Journal Article JACC: CardioOncology · December 1, 2021 Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosc ... Full text Cite

Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial.

Journal Article BMC Fam Pract · November 18, 2021 BACKGROUND: As treatments for cancer have improved, more people are surviving cancer. However, compared to people without a history of cancer, cancer survivors are more likely to die of cardiovascular disease (CVD). Increased risk for CVD-related mortality ... Full text Link to item Cite

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis

Journal Article CJC Open · November 1, 2021 Background: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well establis ... Full text Cite

Povezanost med kazalniki kakovosti življenja ter kazalniki srčnega statusa pri bolnikih, ki prejemajo kemoterapijo

Journal Article Zdravstveno Varstvo · October 20, 2021 Aim: With the aim of improving personalized treatment of patients on chemotherapy, the objective of the study was to assess the degree of association between selected Quality of life (QoL) indicators and both clinical and imaging cardiac status indicators ... Full text Cite

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.

Journal Article Breast Cancer Res Treat · October 2021 PURPOSE: CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase ... Full text Link to item Cite

Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.

Journal Article JACC CardioOncol · September 2021 Radiation therapy is a cornerstone of cancer therapy, with >50% of patients undergoing therapeutic radiation. As a result of widespread use and improved survival, there is increasing focus on the potential long-term effects of ionizing radiation, especiall ... Full text Link to item Cite

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.

Journal Article Curr Oncol Rep · August 27, 2021 PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of ... Full text Link to item Cite

Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association.

Journal Article Circulation · July 20, 2021 With the advent of novel cancer therapeutics and improved screening, more patients are surviving a cancer diagnosis or living longer with advanced disease. Many of these treatments have associated cardiovascular toxicities that can manifest in both an acut ... Full text Link to item Cite

The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic.

Journal Article Curr Oncol Rep · July 14, 2021 PURPOSE OF REVIEW: To give an overview of the role of social media (SoMe) in cardio-oncology during the COVID-19 pandemic. RECENT FINDINGS: SoMe has been critical in fostering education, outreach, awareness, collaboration, dissemination of information, and ... Full text Link to item Cite

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up.

Journal Article Circ Cardiovasc Imaging · June 2021 BACKGROUND: Our goal was to evaluate the ability of cardiovascular magnetic resonance for detecting and predicting cardiac dysfunction in patients receiving cancer therapy. Left ventricular ejection fraction, global and regional strain utilizing fast-strai ... Full text Link to item Cite

Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review.

Journal Article J Am Coll Cardiol · June 1, 2021 Precision medicine has ushered in a new era of targeted treatments for numerous malignancies, leading to improvements in overall survival. Unlike traditional chemotherapy, many molecular targeted antineoplastic agents are available in oral formulation, lea ... Full text Link to item Cite

Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils.

Journal Article J Natl Cancer Inst · May 4, 2021 In response to the coronavirus disease 2019 (COVID-19) pandemic, the Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this exper ... Full text Link to item Cite

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Journal Article J Clin Oncol · May 1, 2021 PURPOSE: APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients with earl ... Full text Link to item Cite

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.

Journal Article Ann Oncol · February 2021 BACKGROUND: The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. PATIENTS AND METHODS: Po ... Full text Link to item Cite

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.

Journal Article Breast Cancer Res Treat · December 2020 PURPOSE: Anthracyclines are frequently used in adjuvant treatment for early-stage breast cancer (ESBC). The purpose of this study was to evaluate cardiotoxic effects in the first five years after treatment with different anthracycline-based regimens. METHO ... Full text Link to item Cite

Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey.

Journal Article Cardiooncology · November 27, 2020 BACKGROUND: Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care in this setting has not been formal ... Full text Link to item Cite

Cardio-Oncology Education and Training: JACC Council Perspectives.

Journal Article J Am Coll Cardiol · November 10, 2020 The innovative development of cancer therapies has led to an unprecedented improvement in survival outcomes and a wide array of treatment-related toxicities, including those that are cardiovascular in nature. Aging of the population further adds to the num ... Full text Link to item Cite

Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Journal Article CA Cancer J Clin · November 2020 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19) ... Full text Link to item Cite

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

Journal Article Eur J Heart Fail · November 2020 Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides c ... Full text Link to item Cite

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

Journal Article Eur J Heart Fail · November 2020 This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratificat ... Full text Link to item Cite

Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond.

Journal Article J Am Heart Assoc · October 20, 2020 Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic and public health crisis. Increasing waves of intermittent infectious outbreaks have dramatically influenced care among broad populations. Over the past 2 decades, there has been a rapid ... Full text Link to item Cite

Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?

Journal Article J Clin Med · March 25, 2020 Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exp ... Full text Open Access Link to item Cite

Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.

Journal Article Am Soc Clin Oncol Educ Book · March 2020 Advances in cancer screening and improved treatment approaches have led to an increase in survivorship and, consequently, recognition of an association between cancer treatments and the development of cardiovascular complications. In addition, as the popul ... Full text Link to item Cite

Abstract P5-14-11: Cardiac monitoring in advanced breast cancer patients treated with trastuzumab: Does it improve cardiac safety?

Conference Cancer Research · February 15, 2020 AbstractBackground: Trastuzumab (T) has improved patient (pt) outcomes in HER2+ breast cancer (BC) but carries a risk of cardiotoxicity. In the adjuvant setting, guidelines recommend cardiac monitoring (CM) ... Full text Cite

Abstract P5-14-18: Cardioprotective therapy in breast cancer patients with subclinical and clinical cardiotoxicty

Conference Cancer Research · February 15, 2020 AbstractBackground: Modern breast cancer (BC) therapies have led to significant improvement in disease free and overall survival, but are associated with off target toxicity including cardiotoxicity. Current ... Full text Cite

Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.

Journal Article Clin Breast Cancer · February 2020 Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR+/HER ... Full text Link to item Cite

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Journal Article Ann Oncol · February 2020 Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically ... Full text Link to item Cite

Cardio-oncology in clinical studies and real life.

Journal Article Semin Oncol · December 2019 Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent dis ... Full text Link to item Cite

Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology.

Journal Article JACC CardioOncol · December 2019 The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we p ... Full text Link to item Cite

Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events.

Journal Article Int J Cardiol · August 15, 2019 BACKGROUND: In breast cancer patients, coincidental detection of CAC at chest CT may be important in determining cardiovascular (CV) outcomes and facilitate CV disease primary prevention strategies. METHODS: 408 consecutive breast cancer patients referred ... Full text Link to item Cite

Cardiotoxicities of Modern Treatments in Breast Cancer.

Journal Article Curr Treat Options Cardiovasc Med · June 15, 2019 PURPOSE OF REVIEW: This paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health. RECENT FINDINGS: Established and novel ... Full text Link to item Cite

Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study.

Journal Article Curr Oncol · June 2019 INTRODUCTION: Cardiovascular disease is the 2nd leading cause of long-term morbidity and mortality in cancer survivors. Cardio-oncology clinics (cocs) have emerged to address the issue; however, there is a paucity of data about the demographics and clinica ... Full text Link to item Cite

Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.

Journal Article Curr Oncol · June 2019 BACKGROUND: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and obesity are known risk factors for cardiovascular disease. Studies have ... Full text Link to item Cite

Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?

Journal Article Curr Treat Options Cardiovasc Med · May 31, 2019 PURPOSE OF REVIEW: To review cardiotoxicity of and strategies to prevent cardiotoxicity from anthracyclines and anti-HER2 agents used to treat breast cancer. RECENT FINDINGS: Although not common, cardiotoxicity from anthracyclines and anti-HER2 therapies i ... Full text Link to item Cite

Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.

Journal Article J Eval Clin Pract · April 2019 OBJECTIVE: The three Magee Equations provide an estimate of the Oncotype DX recurrence score using commonly available clinicopathologic information (tumour size, grade, oestrogen receptor, progesterone receptor, HER2, and Ki67). We assessed whether integra ... Full text Link to item Cite

Shared medical appointments for patients with a nondiabetic physical chronic illness: A systematic review.

Journal Article Chronic Illn · March 2019 OBJECTIVES: Shared medical appointments are group appointments, with an optional individual consultation, for patients diagnosed with chronic illnesses. Shared medical appointments improve diabetes management, but little is known about their use for other ... Full text Link to item Cite

A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.

Journal Article Curr Oncol · February 2019 Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is ass ... Full text Link to item Cite

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.

Journal Article J Cancer · 2019 Inflammatory breast cancer (IBC) is an understudied and aggressive form of breast cancer with a poor prognosis, accounting for 2-6% of new breast cancer diagnoses but 10% of all breast cancer-related deaths in the United States. Currently there are no ther ... Full text Open Access Link to item Cite

Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Journal Article Curr Oncol · December 2018 Breast cancer is the most common cancer in women, with 15%-25% of those tumours overexpressing the human epidermal growth factor receptor 2 (her2), which is associated with more aggressive disease. On rare occasions, patients present with a paraneoplastic ... Full text Link to item Cite

Reporting of coronary artery calcification on chest CT studies in breast cancer patients at high risk of cancer therapy related cardiac events

Journal Article IJC Heart and Vasculature · March 1, 2018 Background: The identification of coronary artery calcification (CAC) detected coincidentally on chest CT exams could assist in cardiovascular risk assessment but may not be reported consistently on clinical studies. Cardiovascular risk factor stratificati ... Full text Cite

Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.

Journal Article Circulation · February 20, 2018 Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women's health. CVD and breast cancer have several overlapping risk factors, such as obesity and smoking. Ad ... Full text Link to item Cite

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Journal Article Breast Cancer Res Treat · January 2018 BACKGROUND: Pelareorep, a serotype 3 reovirus, has demonstrated preclinical and early clinical activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents. This multicentre, randomized, phase II trial was undertaken to ev ... Full text Link to item Cite

Symptom practice guide for telephone assessment of patients with cancer treatment-related cardiotoxic dyspnea: Adaptation and evaluation of acceptability

Journal Article Cardio-Oncology · December 1, 2017 Background: Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experiencing dyspnea in both the cardiology a ... Full text Cite

The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.

Journal Article Curr Oncol · October 2017 INTRODUCTION: Patients with breast cancer (bca) who overexpress her2 (the human epidermal growth factor receptor 2) are at risk for cardiotoxicity when treated with anthracycline-based chemotherapy and her2-targeted agents. The Framingham risk score (frs) ... Full text Link to item Cite

A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.

Journal Article Clin Pharmacokinet · September 2017 OBJECTIVE: The aim of this study was to evaluate the pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and relevant analytes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and hepatic impairment. MET ... Full text Link to item Cite

Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.

Journal Article Curr Oncol · June 2017 BACKGROUND: Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important considerat ... Full text Link to item Cite

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Journal Article J Clin Oncol · March 10, 2017 Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the patient with cancer. The purpose of this effort w ... Full text Link to item Cite

Coordinating Cardio-Oncology Care

Chapter · January 1, 2017 Cardiotoxicity is now the second leading cause of long-term morbidity and mortality among cancer survivors. The discipline of cardio-oncology has developed in response to the combined decision-making necessary to optimize the care of patients with cancer, ... Full text Cite

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.

Journal Article Can J Cardiol · July 2016 Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morb ... Full text Link to item Cite

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.

Journal Article CA Cancer J Clin · July 2016 Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, the ... Full text Link to item Cite

Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.

Journal Article Support Care Cancer · July 2016 BACKGROUND: The US Oncology Trial 9735 (doxorubicin and cyclophosphamide (AC) versus docetaxel and cyclophosphamide (TC)) reported febrile neutropenia (FN) in 5 % of patients receiving TC chemotherapy, in the absence of routine primary prophylaxis with gra ... Full text Link to item Cite

Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty.

Journal Article J Card Fail · June 2016 There is an increasing awareness and clinical interest in cardiac safety during cancer therapy as well as in optimally addressing cardiac issues in cancer survivors. Although there is an emerging expertise in this area, known as cardio-oncology, there is a ... Full text Link to item Cite

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

Journal Article JAMA Oncol · June 1, 2016 IMPORTANCE: The expense and lengthy follow-up periods for randomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical and even impossible to conduct. Randomized clinical trials of neoadjuvant systemic therapy for b ... Full text Link to item Cite

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.

Journal Article Breast Cancer Res Treat · May 2016 In murine models, overexpression of the MET receptor transgene induces tumors with human basal gene expression characteristics supporting MET inhibition as a treatment strategy for triple-negative breast cancer (TNBC). Foretinib is an oral multi-kinase inh ... Full text Link to item Cite

Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Journal Article JAMA Oncol · February 2016 IMPORTANCE: Despite multiple patient-centered factors being associated with the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely considered when making antiemetic recommendations. OBJECTIVE: To compare risk model-guided (RM ... Full text Link to item Cite

Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study

Journal Article Current Oncology · January 1, 2016 Introduction The accrual rate to clinical trials in oncology remains low. In this exploratory pilot study, we prospectively assessed the role that engaging a referring surgeon plays in enhancing nonsurgical oncologic clinical trial accrual. Methods Newly d ... Full text Cite

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.

Journal Article Breast Cancer Res Treat · January 2016 Previous studies suggest switching from pamidronate to a more potent bone-targeted agent is associated with biomarker and palliative response in breast cancer patients with bone metastases. Until now, this has not been addressed in a double-blind, randomiz ... Full text Link to item Cite

Cardiotoxicity in breast cancer patients: A single center, retrospective review

Journal Article Progress in Pediatric Cardiology · November 1, 2015 While advances in breast cancer treatment, including targeted therapies, have improved patient outcomes, such treatments may be associated with both short and long term toxicity. In 2008, The Ottawa Hospital cardiac oncology clinic was established with the ... Full text Cite

Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study.

Journal Article CMAJ · September 8, 2015 BACKGROUND: Practice guidelines recommend that imaging to detect metastatic disease not be performed in the majority of patients with early-stage breast cancer who are asymptomatic. We aimed to determine whether practice patterns in Ontario conform with th ... Full text Link to item Cite

Duration of Trastuzumab. In matters of the heart, one size may not fit all?

Journal Article Eur J Cancer · September 2015 The PHARE trial was initially reported in 2013 and demonstrated that 6 months of Trastuzumab therapy was inferior to 12 months of therapy in terms of reducing risk of Her2+ breast cancer recurrence. Updated results of this study have been presented and dem ... Full text Link to item Cite

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

Journal Article J Clin Oncol · May 10, 2015 PURPOSE: The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown. PATIENTS AND METHODS: The MA.31 trial compared a co ... Full text Link to item Cite

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

Journal Article Curr Oncol · March 2015 The Breast Cancer Disease Site Group of Cancer Care Ontario identified the need for new guidelines for the adjuvant systemic therapy of early-stage breast cancer. The specific question to be addressed was "What is the optimal adjuvant systemic therapy for ... Full text Link to item Cite

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Journal Article Curr Oncol · March 2015 BACKGROUND: This systematic review addresses the question "What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer?" METHODS: The medline and embase databases were sea ... Full text Link to item Cite

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Journal Article Curr Oncol · March 2015 BACKGROUND: Cancer Care Ontario's Program in Evidence-Based Care (pebc) recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to answer ... Full text Link to item Cite

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Journal Article Curr Oncol · March 2015 BACKGROUND: The Program in Evidence-Based Care (pebc) of Cancer Care Ontario recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to a ... Full text Link to item Cite

Locoregional therapy of locally advanced breast cancer: A clinical practice guideline

Journal Article Current Oncology · March 1, 2015 Questions 1. In female patients with locally advanced breast cancer (LABC) and good response to neoadjuvant chemotherapy (NACT), including endocrine therapy, what is the role of breast-conserving surgery (BCS) compared with mastectomy? 2. In female patient ... Full text Cite

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.

Journal Article J Med Econ · March 2015 OBJECTIVE: The NeoSphere trial demonstrated that the addition of pertuzumab to trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer (eBC) resulted in a significant improvement in pa ... Full text Link to item Cite

Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.

Journal Article J Oncol Pract · March 2015 PURPOSE: Adjuvant chemotherapy is considered standard care for patients with lymph node (LN) -positive and high-risk LN-negative early breast cancer (EBC). Although chemotherapy-associated toxicities are documented in clinical trials, the impact of toxicit ... Full text Link to item Cite

Cancer and Cardiovascular Disease: The Complex Labyrinth

Journal Article Journal of Oncology · January 1, 2015 Full text Cite

An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy

Journal Article Journal of Oncology · January 1, 2015 Cardiotoxicity is the second leading cause of morbidity and mortality in cancer survivors. The objective of this international cardiac oncology survey was to gain a better understanding of current knowledge and practice patterns among HCPs involved in the ... Full text Cite

Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study

Journal Article Journal of Oncology · January 1, 2015 Cardiotoxicity is the second leading cause of long-Term morbidity and mortality among cancer survivors. The purpose of this retrospective observational study is to report on the clinical and cardiac outcomes in patients with early stage and advanced cancer ... Full text Cite

Novel agents and associated toxicities of inhibitors of the PI3k/Akt/mtor pathway for the treatment of breast cancer

Journal Article Current Oncology · January 1, 2015 The pi3k/Akt/mtor (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling pathway is an established driver of oncogenic activity in human malignancies. Therapeutic targeting of this pathway holds significant promise as a treatment str ... Full text Cite

Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.

Journal Article Eur J Cancer · October 2014 BACKGROUND: Oncotype DX recurrence score is a multi-gene assay which quantifies the risk of distant recurrence in patients with hormone receptor-positive (HR+) early breast cancer (EBC) treated with tamoxifen, and predicts the magnitude of clinical benefit ... Full text Link to item Cite

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Journal Article Breast Cancer Res Treat · April 2014 The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3-4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with s ... Full text Link to item Cite

Neoadjuvant chemotherapy in breast cancer: what questions remain?

Journal Article Curr Opin Support Palliat Care · March 2014 PURPOSE OF REVIEW: Although neoadjuvant therapy (NAT) has become a popular approach in the systemic management of breast cancer, several important clinical questions remain unanswered. In this article, we review the literature pertaining to these questions ... Full text Link to item Cite

Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.

Journal Article Oncologist · February 2014 OBJECTIVE: Our objective was to evaluate preferences associated with grade I/II and grade III/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. We also assessed trade-offs that patients are willing to make between treatment ... Full text Link to item Cite

Competing risks of death in younger and older postmenopausal breast cancer patients

Journal Article World Journal of Clinical Oncology · January 1, 2014 AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramus ... Full text Cite

Treatment outcomes for male breast cancer: A single-centre retrospective case-control study

Journal Article Current Oncology · January 1, 2014 Background Male breast cancer (bc) is a rare disease, and the availability of information on treatment outcomes is limited compared with that for female bc. The objective of the present study was to compare disease-free (dfs) and overall survival (os) for ... Full text Cite

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression

Journal Article Oncology Letters · January 1, 2014 Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when c ... Full text Cite

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

Journal Article Invest New Drugs · December 2013 PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmac ... Full text Link to item Cite

Preference weights for chemotherapy side effects from the perspective of women with breast cancer.

Journal Article Breast Cancer Res Treat · November 2013 Perceptions among women with breast cancer about the relative importance of different potential chemotherapy side effects is not well understood. A survey was performed by women receiving chemotherapy for breast cancer. Grade I/II (mild to moderate) and II ... Full text Link to item Cite

HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.

Journal Article Cancer Treat Rev · October 2013 Targeting human epidermal growth factor receptor 2 (HER2) during or in sequence with chemotherapy improves overall survival in metastatic and early HER2-overexpressing breast cancer. In this paper we systematically review neoadjuvant clinical trial data in ... Full text Link to item Cite

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.

Journal Article Breast Cancer Res Treat · August 2013 The goal of this project was to investigate the contentious issue of a possible effect of endocrine therapy (ET) on sexual dysfunction (SD) in postmenopausal early stage breast cancer survivors. To date, few studies have assessed sexual functioning prior t ... Full text Link to item Cite

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Journal Article J Support Oncol · March 2013 BACKGROUND: Even with modern antiemetic regimens, up to 20% of cancer patients suffer from moderate to severe chemotherapy-induced nausea and vomiting (CINV) (> or = grade 2). We previously developed chemotherapy cycle-based risk predictive models for > or ... Full text Link to item Cite

Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: Experience from a single academic cancer centre

Journal Article Current Oncology · January 1, 2013 Background Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (mbc). This study reports clinical benefit and toxicities experienced by women with mbc treated with nab-paclitaxel at the Ottawa ... Full text Cite

The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: An observational study

Journal Article Cardiology Research and Practice · December 1, 2012 Background. We established a dedicated cardiac oncology clinic in 2008 for the rapid diagnosis and treatment of cardiotoxicity related to cancer therapy. In this retrospective observational study, we report on clinical outcomes in women with early-stage br ... Full text Cite

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting

Journal Article Current Oncology · January 1, 2012 Background Despite the use of standardized anti-emetic guidelines, up to 20% of cancer patients suffer from moderate-to-severe chemotherapy-induced nausea and vomiting (CINV)-that is, grade 2 or greater according to the U.S. National Cancer Institute Commo ... Full text Cite

Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience

Journal Article Current Oncology · January 1, 2012 Background: Use of granulocyte colony-stimulating factor (g-CSF) as primary prophylaxis against chemotherapy-induced neutropenia has significant cost implications. We examined use of g-csf for early-stage breast cancer patients at our centre. The study als ... Full text Cite

Excision of the primary tumour in patients with metastatic breast cancer: A clinical dilemma

Journal Article Current Oncology · January 1, 2012 Background: Approximately 10% of new breast cancer patients will present with overt synchronous metastatic disease. The optimal local management of those patients is controversial. Several series suggest that removal of the primary tumour is associated wit ... Full text Cite

Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.

Journal Article J Clin Oncol · December 20, 2011 PURPOSE: An Institute of Medicine report recommends that patients with cancer receive a survivorship care plan (SCP). The trial objective was to determine if an SCP for breast cancer survivors improves patient-reported outcomes. PATIENTS AND METHODS: Women ... Full text Link to item Cite

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

Journal Article J Clin Oncol · October 10, 2011 PURPOSE: Somatostatin analogs act directly on breast cancer cells and indirectly on insulin and insulin-like growth factor 1 (IGF-1) levels. This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of brea ... Full text Link to item Cite

Acquisition of metastatic tissue from patients with bone metastases from breast cancer.

Journal Article Breast Cancer Res Treat · October 2011 Biopsies of metastatic tissue are increasingly being performed. Bone is the most frequent site of metastasis in breast cancer patients, but bone remains technically challenging to biopsy. Difficulties with both tissue acquisition and techniques for analysi ... Full text Link to item Cite

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.

Journal Article Breast Cancer Res Treat · April 2011 Aromatase inhibitors (AIs) have been shown to reduce the risk of breast cancer recurrence and are widely used today as adjuvant therapy in women with early stage endocrine-responsive breast cancer. Aromatase inhibitors may be prescribed as initial hormonal ... Full text Link to item Cite

First annual Canadian cardiac oncology network conference

Journal Article Current Oncology · January 1, 2011 The inaugural Canadian Cardiac Oncology Network conference was held at the Ottawa Convention Centre, Ottawa, Ontario, May 13, 2011. The learning objectives of the meeting were to • understand and appreciate the importance of cardiac toxicity in the treatme ... Full text Cite

Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres

Journal Article Current Oncology · January 1, 2011 Background: The efficacy of adjuvant chemotherapy with FEC-D (5-fluorouracil-epirubicin-cyclophosphamide followed by docetaxel) is superior to that with fec-100 alone in women with early-stage breast cancer. As the use of FEC-D increased in clinical practi ... Full text Cite

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.

Journal Article J Clin Oncol · February 10, 2010 PURPOSE Preclinical studies indicate that metronomic chemotherapy is antiangiogenic and synergistic with other antiangiogenic agents. We designed a phase I/II study to evaluate the safety and activity of adding dalteparin and prednisone to metronomic cyclo ... Full text Link to item Cite

A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.

Journal Article Cancer Chemother Pharmacol · February 2010 PURPOSE: Pemetrexed (PEM) is a novel folate antimetabolite which inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. This phase II study was designed to assess the efficacy of Gemcitabine (GEM) and PEM ... Full text Link to item Cite

Endocrine therapy for male breast cancer: Rates of toxicity and adherence

Journal Article Current Oncology · January 1, 2010 Purpose Most male breast cancer tumours are hormone receptor- positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endocrine t ... Full text Cite

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

Journal Article Oncologist · 2010 PURPOSE: Angiogenesis is an important hallmark of breast cancer growth and progression. Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, has activity across a rang ... Full text Link to item Cite

Optimizing the management of her2-positive early breast cancer: The clinical reality

Journal Article Current Oncology · January 1, 2010 Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of ... Full text Cite

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.

Journal Article Breast Cancer Res Treat · November 2009 Fulvestrant use in pretreated metastatic breast cancer patients is associated with variable response rates. This study aimed to characterize these responses and to develop a prediction model to identify those patients who could potentially derive the most ... Full text Link to item Cite

Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.

Journal Article Clin Cancer Res · January 15, 2009 PURPOSE: Clusterin is an antiapoptotic protein activated in response to cellular stress. OGX-011 is a second-generation antisense oligonucleotide that inhibits clusterin expression. The primary objective of this phase II trial was to assess the safety and ... Full text Link to item Cite

The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer

Journal Article Current Oncology · January 1, 2009 The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), was the first HER2-targeted therapy that clearly demonstr ... Full text Cite

The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers

Journal Article Current Oncology · January 1, 2009 Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improve ... Full text Cite

Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.

Journal Article Cancer Treat Rev · August 2008 Anthracyclines demonstrate significant disease activity in breast cancer and are a key component of therapy in both early and advanced disease. It has been long recognized that these agents are associated with cumulative dose-related cardiotoxicity that of ... Full text Link to item Cite

Toward population-based indicators of quality end-of-life care: testing stakeholder agreement.

Journal Article Cancer · May 15, 2008 BACKGROUND: Quality indicators (QIs) are tools designed to measure and improve quality of care. The objective of this study was to assess stakeholder acceptability of QIs of end-of-life (EOL) care that potentially were measurable from population-based admi ... Full text Link to item Cite

Gemcitabine in the management of metastatic breast cancer: a systematic review.

Journal Article Breast Cancer Res Treat · April 2008 BACKGROUND: A systematic review of the evidence for gemcitabine chemotherapy, alone or in combination, in women with metastatic/advanced breast cancer was undertaken in order to determine gemcitabine's role in the first-line and/or second-line or greater s ... Full text Link to item Cite

Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.

Journal Article J Clin Oncol · March 20, 2008 PURPOSE: We describe issues and outcomes in the development of a specialized, central institutional review board (IRB) for multicenter oncology protocols. Numerous authoritative bodies have called for a change to the ethics review system to better manage m ... Full text Link to item Cite

A Phase 2 study of perifosine in advanced or metastatic breast cancer.

Journal Article Breast Cancer Res Treat · March 2008 BACKGROUND: First- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yield response rates of 20-25%, with ... Full text Link to item Cite

Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group

Journal Article Current Oncology · January 1, 2008 Trastuzumab has been shown to be an effective therapy for women with breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) protein. In the pivotal metastatic breast cancer trials, cardiac dysfunction was observed in women tre ... Full text Cite

Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.

Journal Article J Clin Oncol · February 20, 2006 PURPOSE: Most women with breast cancer are diagnosed at an early stage and more than 80% will be long-term survivors. Routine follow-up marks the transition from intensive treatment to survivorship. It is usual practice for routine follow-up to take place ... Full text Link to item Cite

Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.

Journal Article Lung · 2005 Troxacitabine. a promising new L-nucleoside, inhibits DNA polymerase and leads to complete DNA chain termination. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) conducted a phase II study to assess the efficacy and toxicity of tro ... Full text Link to item Cite

Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).

Journal Article Invest New Drugs · January 2005 BACKGROUND: The primary objective of this Phase I study was to determine the maximum tolerated dose (MTD) and recommended phase II dose for Tomudex and Doxorubicin when given in combination to patients with advanced metastatic cancer. The secondary objecti ... Full text Link to item Cite

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

Journal Article J Clin Oncol · January 15, 2004 PURPOSE: N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is a novel agent that augments chemotherapy cytotoxicity in vitro and in vivo. A phase II trial combining DPPE and doxorubicin (DOX) in metastatic breast carcinoma showed increa ... Full text Link to item Cite

Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.

Journal Article J Natl Cancer Inst · April 16, 2003 BACKGROUND: In recent years, patients have indicated a desire for more information about their disease and to be involved in making decisions about their care. We developed an aid called the "Decision Board" to help clinicians inform patients with lymph no ... Full text Link to item Cite

Application of a new multinomial phase II stopping rule using response and early progression.

Journal Article J Clin Oncol · February 1, 2001 PURPOSE: A multinomial stopping rule had previously been developed that incorporated both objective response and early progression into decisions to stop or continue phase II trials of anticancer agents. The purpose of this study was to apply the multinomi ... Full text Link to item Cite

Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG).

Journal Article Ann Oncol · January 2000 BACKGROUND: Ovarian cancer is the leading cause of death from gynecological malignancies and the fourth most frequent fatal malignancy in women. Despite improved surgical techniques as many as 20% of women with early stage disease will eventually relapse a ... Full text Link to item Cite

Phase II trial of N,N-diethyl,2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study

Journal Article Journal of Clinical Oncology · January 1, 1999 Purpose: This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist, N,N-diethyl-2-[4(phenylmethyl)phenoxy]ethanamine.HCl (DPPE), and doxorubicin in patients with anthracycline-na ... Full text Cite

Phase I trial design: are new methodologies being put into practice?

Journal Article Ann Oncol · August 1996 BACKGROUND: The primary goal of phase I studies is to efficiently and accurately determine the recommended dose of a new agent for further investigation. Issues of concern ranging from the ethics of these trials to selection of starting dose and rapidity o ... Full text Link to item Cite

PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.

Journal Article J Neurooncol · April 1996 UNLABELLED: We conducted a Phase II study of PROMACE-MOPP and intrathecal (IT) therapy followed by cranial radiation in 7 patients (4 male, 3 females) with diffuse large cell lymphomas (including one T cell) involving the central nervous system (CNS). Medi ... Full text Link to item Cite